ATE319810T1 - Durchflussverfahren zur herstellung von mikropartikeln - Google Patents

Durchflussverfahren zur herstellung von mikropartikeln

Info

Publication number
ATE319810T1
ATE319810T1 AT00978814T AT00978814T ATE319810T1 AT E319810 T1 ATE319810 T1 AT E319810T1 AT 00978814 T AT00978814 T AT 00978814T AT 00978814 T AT00978814 T AT 00978814T AT E319810 T1 ATE319810 T1 AT E319810T1
Authority
AT
Austria
Prior art keywords
nucleic acid
therapy
microparticles
continuous flow
microparticle
Prior art date
Application number
AT00978814T
Other languages
English (en)
Inventor
Mary Lynne Hedley
Yung-Yueh Hsu
Michael Tyo
Original Assignee
Zycos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zycos Inc filed Critical Zycos Inc
Application granted granted Critical
Publication of ATE319810T1 publication Critical patent/ATE319810T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
AT00978814T 1999-11-19 2000-11-17 Durchflussverfahren zur herstellung von mikropartikeln ATE319810T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44365499A 1999-11-19 1999-11-19

Publications (1)

Publication Number Publication Date
ATE319810T1 true ATE319810T1 (de) 2006-03-15

Family

ID=23761667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978814T ATE319810T1 (de) 1999-11-19 2000-11-17 Durchflussverfahren zur herstellung von mikropartikeln

Country Status (8)

Country Link
EP (1) EP1230338B1 (de)
JP (1) JP2003514832A (de)
AT (1) ATE319810T1 (de)
AU (1) AU783918B2 (de)
CA (1) CA2389613A1 (de)
DE (1) DE60026571T2 (de)
ES (1) ES2260070T3 (de)
WO (1) WO2001036583A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6815901A (en) * 2000-06-02 2001-12-17 Zycos Inc Delivery systems for bioactive agents
WO2004037175A2 (en) 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
WO2004060363A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for producing sterile polynucleotide based medicaments
EP1578193A4 (de) * 2002-12-23 2011-06-15 Vical Inc Gefriertrocknungsverfahren für nukleinsäure-/blockcopolymer-/kationtensid-komplexe
AU2004286232A1 (en) * 2003-10-23 2005-05-12 Alza Corporation Compositions of stabilized DNA for coating microprojections
RU2442822C2 (ru) 2005-01-25 2012-02-20 Вайет Рисерч Айрлэнд Лимитед Вещества, защищающие клетки от рассечения при сборе микрофильтрацией
ATE539102T1 (de) 2006-10-31 2012-01-15 Surmodics Pharmaceuticals Inc Kugelförmige polymer-partikel
EP2389160B1 (de) * 2009-01-23 2017-09-13 Evonik Corporation Kontinuierliches doppelemulsionsverfahren zur herstellung von mikroteilchen
US20120100207A1 (en) * 2009-07-02 2012-04-26 Konica Minolta Holdings, Inc. Process for producing liposomes by two-step emulsification method utilizing outer aqueous phase containing specific dispersing agent, process for producing liposome dispersion or dry powder thereof using the process for producing liposomes, and liposome dispersion or dry powder thereof produced thereby
KR101543507B1 (ko) * 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
KR102283250B1 (ko) * 2020-12-24 2021-07-29 (주)인벤티지랩 용매 제거 장치 및 이를 이용한 미소구체 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
EP0862419B2 (de) * 1995-11-09 2010-11-17 Microbiological Research Authority Mikroverkapselte dna zur impfung und gentherapie
GB2310801A (en) * 1996-03-04 1997-09-10 Merck & Co Inc Process for removing an organic solvent from lactide-glycoside copolymer microspheres
EP1005374B1 (de) * 1997-01-22 2007-04-18 Zycos Inc. Mikropartikel zur verabreichung von nukleinsaeuren
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
NZ504188A (en) * 1997-11-14 2001-10-26 Skyepharma Inc Emulsification process for preparing multivesicular liposomes
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
WO1999045966A1 (en) * 1998-03-13 1999-09-16 American Home Products Corporation Polynucleotide composition, method of preparation, and use thereof

Also Published As

Publication number Publication date
EP1230338B1 (de) 2006-03-08
EP1230338A1 (de) 2002-08-14
JP2003514832A (ja) 2003-04-22
DE60026571D1 (de) 2006-05-04
ES2260070T3 (es) 2006-11-01
DE60026571T2 (de) 2006-12-14
CA2389613A1 (en) 2001-05-25
EP1230338A4 (de) 2004-03-31
AU783918B2 (en) 2005-12-22
WO2001036583A1 (en) 2001-05-25
AU1623401A (en) 2001-05-30

Similar Documents

Publication Publication Date Title
ATE319810T1 (de) Durchflussverfahren zur herstellung von mikropartikeln
HUP9901874A2 (hu) Humán TNFalfa-t kötő antitestek
ATE192500T1 (de) Rekombinante viren vektoren zur expression in muskelzellen
ES2091768T3 (es) Factor neurotrofico ciliar purificado.
HUP0101948A2 (hu) Il-2-szelektív agonisták és antagonisták
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
EP1392835A4 (de) Epressionsvektor für tierische zellen
HK1071161A1 (en) Noninvasive genetic immunization by topical application of bacterial vectors
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
NZ223506A (en) Tissue factor protein, dna encoding it, vectors, host cells, production of the protein and pharmaceutical compositions
NZ531570A (en) DNA sequences for human angiogenesis genes
HUP0100314A2 (hu) Hepatocita proliferációs aktivitással rendelkező fibroblaszt növekedési faktor
DE69821793D1 (de) Neuronale verwendungen des bmp-11
AP2000001999A0 (en) Gene therapy method.
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
MXPA03008210A (es) Produccion de altos niveles del factor ix transgenico sin rescate del gen, y sus usos terapeuticos.
IE883188L (en) Mutant acidic fibroblast growth factor
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE509104T1 (de) Verfahren zur herstellung von mikroverkapselter dna zur impfung und gentherapie
MX9805158A (es) Adn que codifica una proteina activadora de plasminogeno.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties